A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that predominantly affects children and adolescents. The test is being developed by researchers funded by British charity Cancer Research UK for Ewing sarcoma, a rare cancer with a high risk of spreading that can evade modern scanning techniques. Read more: https://www.fiercebiotech.com/medtech/blood-test-powered-ai-shows-early-promise-monitoring-rare-child

In multiple models of Ewing sarcoma—a rare and aggressive cancer affecting children and young adults—the treatment eliminated established tumors and dramatically reduced the spread of cancer. Read more: https://medicalxpress.com/news/2026-04-therapy-aggressive-childhood-adult-cancers.html

A new clinical trial led by the Penn State College of Medicine–based Beat Childhood Cancer Research Consortium will evaluate whether the drug eflornithine (DFMO) can help prevent relapse and improve outcomes for patients with Ewing sarcoma and osteosarcoma — two aggressive bone cancers that have seen few meaningful treatment advances in decades, according to Giselle Saulnier Sholler, MD, MSc, chair and founder of the consortium. Read more: https://pennstatehealthnews.org/2026

A groundbreaking study led by researchers at Children’s Hospital Los Angeles offers critical insights into Ewing Sarcoma, a rare and aggressive bone and soft tissue cancer that primarily affects children and adolescents. Read more: https://www.morningstar.com/news/business-wire/20251013103275/childrens-hospital-los-angeles-researchers-discover-possible-cell-of-origin-for-ewing-sarcoma

While surgery and radiation therapy are generally successful in treating Ewing sarcoma, difficult-to-treat and relapsed cases still...

Ewing’s sarcoma, osteosarcoma, and other bone cancers often impinge upon the growth plates of children’s arms and legs, explained...

A new study led by Ana Losada, head of the Chromosomal Dynamics Group at Spain’s National Cancer Research Centre (CNIO), identifies...

The FDA granted a rare pediatric disease designation to elraglusib (9-ING-41), a novel GSK-3β inhibitor, as a potential therapeutic...

Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered a new drug target for Ewing sarcoma, a rare kind of cancer usually...

High doses of drug called ifosfamide are the best way to treat a cancer of children which affects bones and soft tissues, compared to ...